Oncology | Phase II/ Phase III Developments

TG Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TG Therapeutics Gets FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Marginal Zone Lymphoma and Follicular Lymphoma

Lead Product(s): Umbralisib

Therapeutic Area: Oncology Product Name: TGR-1202

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 13, 2020

Details:

U.S. FDA has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL).

Tyme Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer

Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin

Therapeutic Area: Oncology Product Name: SM-88

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

SM-88 has demonstrated encouraging tumor responses in 15 different cancers across four separate studies with minimal serious grade 3 or higher adverse events .

Tyme Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results

Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin

Therapeutic Area: Oncology Product Name: SM-88

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2020

Details:

TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer.

MacroGenics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

Lead Product(s): Margetuximab,Retifanlimab,MGD013

Therapeutic Area: Oncology Product Name: MGAH22

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

Lancet Oncology has published results from a Phase 2 study of margetuximab plus pembrolizumab as a chemotherapy-free regimen for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) who have previously been treated with chemotherapy and trastuzumab.

Y-mAbs Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Lead Product(s): Omburtamab

Therapeutic Area: Oncology Product Name: 131I-8H9

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

Omburtamab is an investigational, mAb that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types. The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma.

DelMar Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation

Lead Product(s): Dianhydrogalactitol

Therapeutic Area: Oncology Product Name: VAL-083

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: National Brain Tumor Society

Deal Size: $0.5 million Upfront Cash: Undisclosed

Deal Type: Funding June 24, 2020

Details:

This loan aims to support VAL-083’s preparation for participation in the Global Coalition for Adaptive Research’s sponsored trial, Glioblastoma Adaptive Global Innovative Learning Environment study.

Tyme Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020

Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin

Therapeutic Area: Oncology Product Name: SM-88

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Oral SM-88 is designed to selectively disrupt cancer’s metabolic process and cause cancer cell death; SM-88 is currently in a pivotal trial for 3rd-line pancreatic cancer. Preclinical data shows statistically significant tumor reduction in SM-88 treated arms versus controls.

Nanobiotix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Nanobiotix Secures €10M in Non-Dilutive Financing

Lead Product(s): Hafnium dioxide

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: HSBC

Deal Size: $11.1 million Upfront Cash: Undisclosed

Deal Type: Financing June 08, 2020

Details:

The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.

MacroGenics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer

Lead Product(s): Margetuximab,INCMGA00012,MGD013

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2020

Details:

Margetuximab is currently being evaluated in the Phase 2/3 MAHOGANY clinical trial in combination with checkpoint inhibition, with/without chemotherapy, as a first-line treatment for patients with HER2-positive gastric cancer or gastroesophageal junction cancer.

Tyme Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting

Lead Product(s): Methyltyrosine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Lead pipeline investigational compound, SM-88, represents a new approach designed to selectively disrupt cancers metabolic process leading to cancer cell death SM-88 has demonstrated clinical responses in 15 different cancer types across four separate studies.

Find

Find Oncology Drugs in Phase II/III Clinical Development

Phase II/ Phase III

Product Type

Companies

TG Therapeutics

TG Therapeutics Gets FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Marginal Zone Lymphoma and Follicular Lymphoma

Tyme Technologies

TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer

Tyme Technologies

TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results

MacroGenics

MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

Y-mAbs Therapeutics

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

DelMar Pharmaceuticals

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation

Tyme Technologies

TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020

Nanobiotix

Nanobiotix Secures €10M in Non-Dilutive Financing

MacroGenics

MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer

Tyme Technologies

TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting